key: cord-0782921-5vqchwi2
authors: Fallouh, Nabil A.; Naik, Katrina H.; Udochi, Chichi O.; Horowitz, Adam Z.; Ayanian, Shant; Humes, Kathryn M.; Izzi, Farida M.; Borum, Marie L.; Reyes, Juan A.
title: Better clinical outcomes in hospitalized COVID-19 minority patients with accompanying gastrointestinal symptoms
date: 2021-06-25
journal: J Natl Med Assoc
DOI: 10.1016/j.jnma.2021.05.016
sha: 6b35ebc3d46ff849a2862ae101d2b8b489549940
doc_id: 782921
cord_uid: 5vqchwi2

BACKGROUND AND AIMS: The novel coronavirus (SARS-CoV-2) is highly contagious pathogen that primarily causes respiratory illnesses. Howerver, multiple gastrointestinal (GI) symptoms have been reported in Coronavirus Disease of 2019 (COVID-19). We conducted a retrospective cohort study of inpatients with COVID-19 at the George Washington University Hospital (GWUH) to assess the prevalence of GI symptoms and their association with clinical outcomes. METHODS: We reviewed the charts of 401 adults admitted to GWUH with positive SARS-CoV-2 tests from February 24 to May 21, 2020, ultimately including 382 inpatients. RESULTS: 87% of our cohort was African American or Latinx. 59% of patients reported at least one GI symptom, with diarrhea being the most common (29%). Patients with GI symptoms were slightly younger (58 +/- 15.8 vs. 65 +/- 16.9, p = 0.0005), have higher body mass index (31.5 +/- Standard Deviation of 8.7 vs. 28 +/- 8.2, p = 0.0001), and more likely to be Latinx (34 vs. 27, p = 0.01). Patients who presented with abdominal pain, nausea, vomiting, or diarrhea had significantly lower rates of death during hospitalization compared to those who did not present those symptoms (Odds Ratio 0.48, 95% Confidence Interval 0.28–0.8, p = 0.004). CONCLUSIONS: Our study suggests that GI symptoms portend a less-severe clinical course of COVID-19 which may reflect a different disease phenotype and lower overall immune response. Additional research should focus on more robust symptom reporting and longer follow-up.

T he Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) that causes Coronavirus Disease of 2019 (COVID-19) is a highly transmissible disease that has resulted in over three million deaths worldwide and over five hundred thousand deaths in the United States as of May 2021. 1 COVID-19 is primarily believed to be a respiratory illness that most commonly presents with fever, fatigue, and cough, and it can lead to the development of acute respiratory distress syndrome (ARDS) and, in severe cases, other organ failures. 2 Gastrointestinal (GI) symptoms such as abdominal pain, anorexia, nausea, vomiting, diarrhea, anosmia, and ageusia occur in many cases of COVID-19, with some reports describing as many as 75% of all hospitalized COVID-19 patients presenting with one or more GI symptom. 3 Despite the prevalence of such symptoms, however, limited data are available that associate GI symptoms with adverse outcomes such as Intensive Care Unit (ICU) admission, ventilator y suppor t requirement, and death.

Earlier reports from China suggested that the presence of GI symptoms in patients with COVID-19 does not impact hospitalization outcomes ( Table 1 ). In a retrospective study of 204 hospitalized COVID-19 patients in Hubei Province, Pan et al. found no difference in length of hospitalization (17.3 vs 16.8 days, p = 0.73) or mortality (18.5 vs 16.8%, p = 0.76) between patients with and without GI symptoms. 4 In contrast, a retrospective study of 651 patients in Zhejiang Province found a higher likelihood of respiratory failure or ICU requirement (23% vs 8.1%, p < 0.001), ARDS (6.8% vs 2.1%, p = 0.034), and mechanical ventilation (6.8% vs 2.1%, p = 0.034) if COVID-19 patients had GI symptoms at the time of presentation. 5 Similarly, American studies have shown mixed results. Ramachandrana et al. showed no difference in mortality (41.9% vs. 37.8%, p = 0.68) or mechanical ventilation (29% vs. 26.9%, p = 0.82) in their 150 COVID-19 patients who had GI symptoms compared to the ones without GI symptoms admitted to a ter tiar y medical center in Brooklyn, NY. 6 Additionally, a multicenter cohort study in Massachusetts that included a subgroup of 202 COVID-19 patients showed no difference in ICU stay (15.4 vs. 21 .4%, p = 0.28), mechanical ventilation (10.9 vs. 16%, p = 0.22), or mortality (12.2 vs. 22.5%, p = 0.06) when comparing patients with and without GI symptoms. 7 Conversely, a retrospective univariable analysis of 1,059 patients with COVID-19 in Manhattan by Hajifathalian el al found that patients with GI symptoms had lower mortality rates (8.5 vs 16.5%, p = 0.003) and lower risk of the composite of death and ICU admission (28% vs 38%, p = 0.006), suggesting that the presence of GI symptoms on initial presentation may be associated with less • Among patients with COVID-19, the mortality rate of those with GI symptoms was lower than for those without GI symptoms.

Gastroenterology USA Prospective case-control.

Consecutively tested patients in a single tertiary care outpatient center in Baltimore, Maryland. Mostly women (59%), AA (51%) in late 40s.

Prevalence of GI symptoms and comparing these symptoms between who tested positive and negative.

• GI symptoms occurred in 74% of patients (30% with nausea, 50% diarrhea, 53% anorexia, 59% with anosmia and 59% with ageusia).

• The study reflects a less sick population as only 10% were hospitalized.

• No significant difference in hospitalization between patients with or without GI symptoms.

Gastroenterology USA Retrospective cohort.

COVID-19 patients evaluated in the ED, outpatient clinic, or admitted at a tertiary care center in California. Mostly Caucasian (51%) or Hispanic (22%), men (53%), in early 50s.

Prevalence of GI symptoms and association with clinical outcomes.

• 32% of patients had GI symptoms (22% with anorexia, 12% with nausea/vomiting, 12% with diarrhea, and 9% with abdominal pain).

• None developed isolated GI symptoms or GI symptoms as an initial manifestation.

• The study reflects a less sick population as only 28.5% were hospitalized. 11 Given the uncertainty of the effect of the GI symptoms on the natural course of COVID-19 and because this effect may vary based on gender, age, and ethnicity, we conducted a retrospective cohort analysis to identify the rates of GI symptoms in hospitalized COVID-19 patients at the George Washington University Hospital (GWUH) in Washington, D.C. and their association with death, ICU admission, hemodialysis requirement, and intubation. Our aim is to better understand if GI symptoms in the context of hospitalization for COVID-19 might provide prognostic value.

In our retrospective, single-center study, we reviewed the charts of 401 adult patients admitted with a positive SARS-COV-2 on polymerase-chain reaction nasopharyngeal swab testing from Febr uar y 24 to May 21, 2020 to the GWUH, an academic ter tiar y center that serves largely African-American and Latino patients in the District of Columbia. We excluded 19 asymptomatic patients who incidentally tested positive for SARS-COV-2 (example: stab wound victim without infectious symptoms).

On the remaining 382 patients, we collected demog raphic infor mation, symptoms at presentation, and clinical outcomes including hemodialysis requirement, respiratory failure requiring intubation, admission to the ICU, and death. Obtaining symptomatology at presentation was done by reviewing ambulance reports, emergency depar tment documentation, and histor y and physicals documented by the primary service. We defined GI-specific symptoms as presenting with either abdominal pain, nausea, vomiting, or diarrhea at the time of admission.

Our primary focus was to identify the prevalence of GI-specific symptoms in addition to the rates of anorexia, anosmia, and ageusia in our cohort of hospitalized COVID-19 patients. Our secondary analyses included studying the association between GI symptoms and the clinical outcomes listed above. A compound variable was created to account for any GI-specific symptom present and named ANVD; a score of 1 indicates patients presenting with abdominal pain, nausea, vomiting or diarrhea.

The data was curated in an Excel database and loaded onto the free open-source statistical software R. Initial exploratory analysis was carried and the basic demographic characteristics were summarized. All variables were transfor med into binar y variables except of age and body mass index (BMI).

Univariate logistic regression and odds ratios (OR) were calculated for the four outcome variables (death, ICU admission, intubation, and need for hemodialysis). Since patients exhibiting symptoms of ANVD were less likely to die, a multivariate logistic regression was used to elucidate any confounding factors; death was used as the outcome variables while the rest of the variables were used as predictors.

A total of 382 patients who were admitted to the hospital with COVID-19 were included in the analysis. The demographics and medical characteristics of the patients are summarized in Table 2 . Notably, the baseline characteristics and comorbidities were not statistically different among patients presenting with and without abdominal pain, nausea, vomiting, or diarrhea (ANVD) except for age, BMI and Latinx ethnicity. Patients who presented with ANVD were likely to be slightly younger (58 + /-15.8 vs. 65 + /-16.9, p = 0.0005), had higher BMI (31.5 + /standard deviation of 8.7 vs. 28 + /-8.2, p = 0.0001), and more likely to be of Latinx origin (34 vs. 27, p = 0.01).

Overall, 52.9% of patients reported at least one GI symptom and 40.3% reported ANVD. The most common complaint was diarrhea (28.8%), while 24.9% of patients presented with anorexia, 22% with nausea, 17% with vomiting, 11.8% with abdominal pain, 5% with ageusia, and 3.4% with anosmia. Patients who presented with ANVD had clinically significant lower rates of death during hospitalization compared with those who did not (OR 0.48, 95%CI 0.28-0.8, p = 0.004). Fur ther more, presenting with ANVD appeared to purport a lower risk of necessitating ICU care (OR 0.68, 95%CI 0.43-1.08, p = 0.1), requiring hemodialysis (OR 0.35, 95%CI 0.12-1.08, p = 0.06), and needing mechanical ventilation (OR 0.75, 95%CI 0.44-1.29, p = 0.3), albeit not statistically significant ( Table 3 ) . A multivariate logistic regression was carried out with death in hospital as the outcome variable and the rest of the features of the dataset to control for any possible confounders ( Table 4 ) . ANVD, continued to be associated with lower risk of death in the multivariate logistic regression with OR of 0.75, 95%CI 0.16-1.37, and p = 0.014.

In our study of hospitalized COVID-19 minority patients at the GWUH (87% of our cohort was of African American or Latinx), we found that more than half of the admitted patients presented with at least one GI symptom (53%), a finding that is consistent with the body of evidence described in Table 1 . More specifically, 40% of patients presented with either abdominal pain, nausea, vomiting, or diarrhea (ANVD). The most common GI symptom on presentation was diarrhea (29%). Patients in our cohort who suffered from GI symptoms were slightly younger, have higher BMI, and more likely to identify as Latinx. Our analysis revealed that the presence of ANVD upon hospital admission tended to exhibit a lower risk of clinical deterioration such as ICU care, intubation, or hemodialysis, and was associated with a significantly lower rate of death (OR 0.48, 95%CI 0.0.28-0.8, p = 0.004). This protective effect of ANVD carried over in a multivariate logistic regression, which indicates that the chance of having unaccounted confoudners was mimimal (OR 0.75, 95%CI 0.16-1.37, p = 0.014). This stands in contrast to initial studies suggesting worse outcomes associated with patients reporting GI symptoms. 5 Our findings support recent evidence that hospitalized COVID-19 patients presenting with GI symptoms within 72 hours of hospitalization have a lower rate of death and fared better than those who do not. 8 , 11 It is unclear whether presenting with these GI symptoms attenuates the severity of the disease or reflects a less severe presentation or phenotype of the disease itself. Angiotensin-converting enzyme 2 (ACE2) is known to be the functional host receptor for SARS-COV-2 and is expectedly abundant in lung alveolar epithelial cells. 12 However, many other organ systems also express the ACE2 receptor, including the gastrointestinal (GI) tract. 13 Though there have been studies looking at genetic variants among COVID-19 patients of different populations, none have shown any distinct association with patient outcomes of different ethnicities. 14 However, in a case-control study of Italian patients affected by COVID-19, ACE2 genetic variants may contribute to the interindividual clinical variability observed within a similar patient population. 15 Supporting this possibility are reports that ACE2 polymorphisms may reduce the viral binding ability of SARS-COV-2 into the cell, which could modulate SARS-CoV-2 susceptibility. 16 Given the vital interaction between the ACE2 receptor and the SARS-CoV-2 spike protein, and its implication for susceptibility and infection, Kaseb et. al argue that ACE2 genetic variation or mutations could carry a different clinical outcome and change the severity of disease. 17 Cole et. al has also reported on the interesting possibility of the interaction between ACE2 expression and gut microbiota, whereby therapeutic effects of ACE2 can be mediated, in part, by its actions on the GI tract and/or gut microbiome. Though the mechanism of this potential effect remains incompletely understood, these studies describe the evolving role gut microbiota may have on cardiopulmonary health. 18 Lastly, it is possible that these patients with extrapulmonary GI symptoms may elicit a less robust immune response. Laszkowska et. al, demonstrated that COVID-19 patients with GI symptoms had significantly lower inflammatory markers (C-reactive protein, D-dimer and lactate dehydrogenase) which have been associated in prior studies with severe illness and poor clinical outcomes. 11 Our study has some limitations. It is a retrospective analysis at a single academic institution. However, the majority of our patients included in this analysis constituted a significant number of underrepresented minorities, identified as carrying a significant burden of disease and mortality as a result of COVID-19.

Recall and ascertainment bias is also of concern when it comes to reporting of symptoms. In doing our manual chart review, however, we triangulated the history obtained at hospital triage, in EMS reports, ED assessments, and upon admission to obtain a more comprehensive picture and corroborate patients' symptomatology upon hospitalization. This was less likely to occur, however, early on in the pandemic prior to published studies out of China. Lastly, selection bias could overestimate the utility of interpreting GI symptoms upon admission, especially if patients being sent home from the ED do not have a significant amount of associated GI symptoms and were deemed well enough to go home. However, for those practicing in the inpatient setting, this study can aid in not only identifying hospitalized patients that may be at an increased risk of clinical deterioration, but also stratifying risk for those who may fare better-especially when counterbalanced by the challenges associated with a large number of infections and stresses placed on resource utilization.

The strength of our study lies in its large numbers of underrepresented ethnic minorities. Druing the pandemic, these populations endured worse outcomes as COVID-19 more severely impacts patients with underlying untreated conditions. The rates of GI-specific symptoms in our unique study population were comparable to other American and international reports. Importantly, our results are in line with most recent studies that suggest a lessened disease course of hospitalized COVID-19 patients when their presentation is accompanied by GI-specific symptoms compared to the ones presenting with respiratory symptoms alone-a finding that was reproduced in our group of mostly underrepreseentated population.

As more studies corroborate our findings of attenuated COVID-19 severeity in the presence of GI-specific symptoms, we believe that the GI symptoms in admitted COVID-19 patients could become a valuable prognostic tool that might help healthcare providers to effectively triage patients during future waves of this pandemic.

JNMA [mNS

COVID-19 pandemic-a focused review for clinicians

Are gastrointestinal symptoms specific for COVID-19 Infection? A prospective case-control study from the United States. Gastroenterology

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients

Prevalence and characteristics of gastrointestinal symptoms in patients with SARS-CoV-2 infection in the United States: a multicenter cohort study

Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications

Gastrointestinal symptoms and COVID-19: case-control study from the United States. Gastroenterology

Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19

Disease course and outcomes of COVID-19 among hospitalized patients with gastrointestinal manifestations

Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg Infect Dis

The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions

Don't blame the BAME: Ethnic and structural inequalities in susceptibilities to COVID-19

ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

The perfect storm: COVID-19 health disparities in US blacks. J Racial Ethn Health Disparities

The Impact of angiotensin-converting enzyme 2 (ACE2) expression on the incidence and severity of COVID-19 infection

ACE2 and microbiota: emerging targets for cardiopulmonary disease therapy

Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Don't overlook digestive symptoms in patients with

High prevalence of concurrent gastrointestinal manifestations in patients with SARS-CoV-2: early experience from California. Gastroenterology

Study concept and design -Fallouh, Naik, Ayanian, Humes, Izzi, Borum, and Reyes.Data acquisition -Fallouh, Naik, Udochi, Horowitz, Ayanian, Humes, Izzi, and Reyes. Statistical analysis -Fallouh and Ayanian. Manuscript preparation -Fallouh, Naik, Udochi, Horowitz, Ayanian, Humes, Borum, and Reyes.Critical revisions -Fallouh, Borum, and Reyes.

Nabil Fallouh (nfallouh@mfa.gwu.edu) has no conflicts to disclose Katrina Naik (knaik@mfa.gwu.edu) has no conflicts to disclose Chichi Udochi (cudochi@mfa.gwu.edu) has no conflicts to disclose Adam Horowitz (ahorowitz@mfa.gwu.edu) has no conflicts to disclose Shant Ayanian (sayanian@mfa.gwu.edu) has no conflicts to disclose Kathr yn Humes (kr morrison@mfa.gwu.edu) has no conflicts to disclose Farida Izzi (fmizzi@mfa.gwu.edu) has no conflicts to disclose Marie Borum (mborum@mfa.gwu.edu) has no conflicts to disclose Juan Reyes (jreyes@mfa.gwu.edu) has no conflicts to disclose